kabutan

Delta-Fly Pharma rises for fifth straight day on planned FDA talks for DFP-10917

Fri Apr 17, 2026 9:24 am JST Catalyst

Delta-Fly Pharma Inc <4598> extended its winning streak to a fifth straight session. After the close on the 16th, the company announced plans to prepare for talks with the US Food and Drug Administration (FDA) regarding conditional marketing approval, following positive Phase 3 trial results for its DFP-10917 monotherapy in patients with relapsed or refractory acute myeloid leukemia.

The company also plans to discuss a Phase 3 trial for a combination therapy of DFP-10917 and Venetoclax (VEN) with the FDA, following promising Phase 1/2 results. The news fueled investor buying interest.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.

Related Articles